CGRP Inhibitors: A New Hope in Migraine Management

Research Summary

A new guideline from the Hungarian Pain Society and the Hungarian Headache Society highlights the promising role of calcitonin gene-related peptide (CGRP) inhibitors in managing migraines. These inhibitors, including monoclonal antibodies and gepants, offer a novel therapeutic option for both episodic and chronic migraines in Hungary. Based on international guidelines and clinical trials, the guideline suggests CGRP inhibitors as effective and safe first-line acute or preventive treatments, especially when personalized to a patient's needs. While adverse effects are usually mild, therapy effectiveness should be reviewed after three months. A structured treatment approach is anticipated to enhance migraine patients' quality of life.

Study Details

📄 Title: [Joint practical guideline of the Hungarian Pain Society Chronic Headache Working Group and the Hungarian Headache Society on the use of calcitonin gene-related peptide (CGRP)-targeting therapies in migraine].

👥 Research Team: Fehér G et al.

📚 Published In: Orv Hetil

📅 Publication Date: 2025 Dec 14

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.